Clinical Trials Logo

Clinical Trial Summary

The goal of this clinical research study is to find out if receiving a 1-week course of partial breast irradiation (PBI) using proton therapy will cause fewer and/or less severe side effects (such as changes to the appearance of the breast) than a longer course of radiation treatment.

This is an investigational study. Proton radiation therapy is FDA approved and commercially available for breast cancer. Up to 200 women will take part in the study. All will be enrolled at MD Anderson.


Clinical Trial Description

PBI is radiation therapy given only to the area of the breast where the cancer was removed. The study staff will use proton-beam radiation to deliver the radiation therapy dose in a more targeted way than other types of radiation, so that less of the healthy tissue is affected.

Proton-Beam PBI Treatment:

If you take part in this study, you will have proton radiation therapy delivered to the area of the lumpectomy 2 times per day, at least 6 hours apart, for 5 (or rarely 6) working days in a row. You will be placed in a cradle and the beam is aimed at the area of interest. You will not feel anything when the treatment is being delivered. The treatment lasts only a few minutes, but you may be in the treatment room longer because the radiation therapists will need to make sure that you are positioned correctly and that the beam is aimed at the correct area. The study staff will show you a video that helps to explain this process.

Although you will need to be at the proton radiation center 2 times a day for your radiation therapy, you are free to leave the proton radiation center between the 2 treatments, and you should be able to do routine daily activities between treatments. This type of radiation does not stay in your body between treatments or after the final treatment.

End-of-Treatment Tests:

On the last (or next-to-last) day of proton-beam PBI, you will have the following tests performed:

- Your medical history will be recorded, and you will be asked about any side effects you have had.

- You will have a physical exam.

- You and your doctor will each fill out the questionnaire about breast changes.

- Photographs will be taken of your breasts to check the appearance of the treated breast after radiation.

At the end of radiation treatment, you will be asked how much personal time was used and how much personal money you spent during treatment. This will only take a few minutes to complete.

Length of Study:

You will receive 5 weekdays of radiation.

Your participation on the study will be over once you have completed the follow-up visits.

Follow-up Tests:

You are being asked to return to the clinic for follow-up testing for up to a total of 10 years. During the first year, there are 4 follow-up visits: about 2 weeks after treatment, about 6 weeks after treatment, about 6 months after treatment, and about 1 year after treatment. During the second and third year, you will come to the clinic every 6 months, and once a year after that for Years 4-10. Some of these visits may be completed by phone call or email.

During these follow-up visits, the following procedures will occur:

- Your medical history will be recorded, and you will be asked about any side effects you have had.

- You will have a physical exam.

- You and your doctor will each fill out the questionnaire about breast changes. This will only take a few minutes to complete.

- Photographs will be taken of your breasts to check the appearance of the treated breast after radiation.

You will have a mammogram 6 months after treatment, 1 year after treatment, and then once a year after that for up to 10 years (as part of this study). You should continue having mammograms once a year after that, as part of your normal medical follow-up and health screening. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01245712
Study type Interventional
Source M.D. Anderson Cancer Center
Contact Eric A. Strom, MD, BS
Phone 713-563-2300
Status Recruiting
Phase Phase 2
Start date November 15, 2010
Completion date November 1, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT03095352 - A Randomized Phase II Study of Pembrolizumab, an Anti-PD (Programmed Cell Death)-1 Antibody, in Combination With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease Phase 2
Active, not recruiting NCT01472094 - Clinical and Biological Predictors of Chemotherapy Toxicity in Older Adults
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Active, not recruiting NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in People With Metastatic Cancer Phase 2
Recruiting NCT03709134 - Genomic Markers for Measuring Metastatic Risk in Breast Cancer Following Primary Treatment
Recruiting NCT03667716 - COM701 in Subjects With Advanced Solid Tumors Phase 1
Active, not recruiting NCT01857193 - Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer Phase 1
Recruiting NCT01624090 - Mithramycin for Lung, Esophagus, and Other Chest Cancers Phase 2
Recruiting NCT03432429 - REI-EXCISE iKnife Study N/A
Active, not recruiting NCT02139358 - Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer Phase 1/Phase 2
Recruiting NCT03615573 - Survey Study: Financial Impact of Breast Cancer Treatment
Completed NCT03323333 - Psychosocial Intervention Pilot for Partners in BRCA Testing N/A
Terminated NCT01649258 - Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy Phase 1
Withdrawn NCT03285607 - MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer Phase 1
Completed NCT03384511 - The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Phase 4
Recruiting NCT01992432 - Brain Functional MRI in Older Women With Breast Cancer (Brain fMRI-BC)
Completed NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis N/A
Completed NCT00759785 - A Study of Dalotuzumab (MK-0646) in Breast Cancer Patients (MK-0646-013) Phase 1
Not yet recruiting NCT03433313 - Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast Cancer Phase 3